DGAP-News: Proteo, Inc. / Proteo Biotech AG: Further rationale for Elafin treatment in newborn infants - convincing preclinical evidence in a neonatal pulmonary model
(firmenpresse) - DGAP-News: Proteo Biotech AG / Key word(s): Research Update/Study
Proteo, Inc. / Proteo Biotech AG: Further rationale for Elafin
treatment in newborn infants - convincing preclinical evidence in a
neonatal pulmonary model
27.06.2012 / 15:01
---------------------------------------------------------------------
Proteo, Inc. / Proteo Biotech AG: Further rationale for Elafin treatment in
newborn infants - convincing preclinical evidence in a neonatal pulmonary
model
Irvine, CA - Kiel, June 27, 2012 - Proteo, Inc. (OTCBB: PTEO; Frankfurter
Freiverkehr: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG
announced today:
An international group of leading clinically active pulmonary researchers
from the Departments of Pediatrics of the Universities of Stanford, Munich
and Alberta, have published further evidence for the use of Elafin in the
treatment of newborn infants whose lungs are incompletely developed.
Mechanical ventilation of preterm babies with oxygen-rich gas offers
life-saving treatment for newborn infants with respiratory failure, but can
also promote lung injury with a considerable risk of chronic lung disease
in later life. One reason for this is that lung elastin, a key determinant
of lung growth and repair, is disordered by mechanical ventilation. A
therapeutic agent to prevent ventilator-induced neonatal lung injury would
be very helpful for the support of premature infants and improvement of
their prognosis.
In the context of their work on the adverse effects of mechanical
ventilation on neonatal lung development, the scientists worked with
neonatal mice genetically modified to produce Elafin in their vasculature.
These mice were almost completely protected against ventilator-induced lung
inflammation and the structural damage to their lungs was attenuated. The
results of this transgenic animal model confirm previous findings in which
administration of Elafin to wild-type animals had similar effects.
The results strongly suggest that degradation and remodeling of lung
elastin can contribute to defective lung growth in response to mechanical
ventilation and the authors surmise that this degradation might be targeted
therapeutically by Elafin.
Further research on this topic is in progress at Stanford University,
funded by grant from the National Heart, Lung and Blood Institute for the
study of Elafin's ability to treat three distinct lung diseases.
Dr. Oliver Wiedow, who discovered Elafin and founded Proteo:»We are very
confident that these results in animal models can be further substantiated
within the framework of the ongoing intensive research and we hope very
much that one day Elafin will support newborn infants with incompletely
developed lungs«.
Source:
Anne Hilgendorff, Kakoli Parai, Robert Ertsey, G Juliana Rey-Parra, Bernard
Thébaud, Rasa Tamosiuniene, Noopur Jain, Edwin F Navarro, Barry C Starcher,
Mark R Nicolls, Marlene Rabinovitch, and Richard D Bland: Neonatal Mice
Genetically Modified to Express the Elastase Inhibitor Elafin are Protected
Against the Adverse Effects of Mechanical Ventilation on Lung Growth. Am J
Physiol Lung Cell Mol Physiol 2012 [epub ahead of print, article in press]
Further information on the clinical development program for Elafin:
Proteo's pharmaceutical Elafin is a copy of a naturally occurring human
anti-inflammatory substance. It is a natural antagonist of the tissue
destroying enzymes (proteases) that participate in the inflammatory
mechanism of many diseases. Elafin's ability to block the enzymes that
cause these undesirable effects makes it a promising drug for the treatment
of e.g. inflammatory lung diseases and severe reperfusion injury. The
excellent tolerability of intravenously administered recombinant Elafin has
already been demonstrated convincingly in a Phase I clinical trial. The
outcome of a Phase II clinical trial on the treatment of postoperative
inflammatory reactions in esophagus carcinoma show that intravenously
administered Elafin has a very clear positive effect on the period of
recovery: 63 percent of the Elafin treated patients required only one day
of intensive care. All patients in the placebo group needed several days of
postoperative intensive medical care. In addition, Proteo's licensing and
development partner, Minapharm Pharmaceuticals SAE, has initiated a Phase
II clinical trial on the use of Elafin for kidney transplantation patients.
This trial is concerned with the prevention of acute organ rejection and
chronic graft injury (allograft nephropathy). A further clinical trial -
EMPIRE (Elafin Myocardial Protection from Ischaemia Reperfusion Injury), a
placebo-controlled, double-blinded, monocentric Phase-II study with 80
patients - has been started in the third quarter of 2011. The study is
being performed under the supervision of the cardiologist Dr. Peter
Henriksen at NHS Lothian's Edinburgh Heart Centre in association with The
University of Edinburgh, one of the leading European universities in the
area of cardiovascular research. The study is funded by the Medical
Research Council (MRC) and Chest Heart&Stroke Scotland (CHSS) with
funding in excess of 500,000 GBP.
About Proteo:
The company researches, develops and markets compounds for biological and
medical research as well as for use as pharmaceuticals. The main focus is
on anti-inflammatory drugs, in particular on the human protease inhibitor
Elafin. Proteo intends to out-license selected indications and to establish
international strategic alliances in order to open up new fields of
application and for marketing (www.proteo.de).
Forward-looking statements:
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act of 1933
and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to
the safe harbor created by those rules. All statements, other than
statements of fact included in this release, including, without limitation,
statements regarding potential future plans and objectives of the company,
are forward-looking statements that involve risks and uncertainties. There
can be no assurance that such statements will prove to be accurate and
actual results and future events could differ materially from those
anticipated in such statements. Technical complications that may arise
could prevent the prompt implementation of any strategically significant
plan(s) outlined above. The company cautions that these forward looking
statements and risks and uncertainties involved are further qualified by
other factors including, but not limited to those set forth in the
company's Form 10-K filing and other filings with the United States
Securities and Exchange Commission. The company undertakes no obligation to
publicly update or revise any statements in this release, whether as a
result of new information, future events or otherwise.
Contact:
Barbara Kahlke, Ph.D.
Proteo Biotech AG
Am Kiel-Kanal 44
D-24106 Kiel
Germany
Email: info(at)proteo.de
Phone: +49(0)431 8888462
Fax: +49(0)431 8888463
End of Corporate News
---------------------------------------------------------------------
27.06.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate Newsand Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
175654 27.06.2012
Themen in dieser Pressemitteilung:
proteo
inc-proteo-biotech-ag-further-rationale-for-elafin-treatment-in-newborn-infants
convincing-preclinical-evidence-in-a-neonatal-pulmonary-model
Unternehmensinformation / Kurzprofil:
Datum: 27.06.2012 - 15:01 Uhr
Sprache: Deutsch
News-ID 160541
Anzahl Zeichen: 6707
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 406 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Proteo, Inc. / Proteo Biotech AG: Further rationale for Elafin treatment in newborn infants - convincing preclinical evidence in a neonatal pulmonary model"
steht unter der journalistisch-redaktionellen Verantwortung von
Proteo Biotech AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
